First Ever Drug/Bio Combo IND Approved by FDA for Lumbar Fusion | Orthopedics This Week

First Ever Drug/Bio Combo IND Approved by FDA for Lumbar Fusion

Courtesy of Kuros Biosciences

The FDA just approved the first ever Investigational New Drug (IND) application to evaluate a drug/biologic combination product for lumbar interbody fusion of the spine.

On September 3, 2019, Swiss-based Kuros Biosciences AG, announced the FDA approval its IND application to initiate a Phase 2a clinical trial to "evaluate the use of Fibrin-PTH (KUR-113) in single level transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease, with autograft (patient’s own bone) as comparator."

Drug/Biologic Combo

Fibrin, according to the company, is formed "by the conversion of a soluble precursor (fibrinogen) to a solid degradable matrix." Commercially, fibrin sealants (without biologics) have been used for more than 30 years, primarily for the prevention of blood loss during surgical procedures.

The company says Fibrin-PTH consists of a "natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog).”

Kuros has a proprietary technology called TG-Hook Technology, which enables covalent linking of biologics into the fibrin matrix.

"A transglutaminase (TG) enzyme called Factor XIIIa is responsible for cross-linking fibrin molecules, thereby forming a solid matrix, whose normal function is to stop blood loss. Kuros’ products employ this same mechanism to cross-link biologics into fibrin during the formation of the fibrin polymer. The TG-Hook Technology is further designed to release the biologic upon cellular infiltration into the matrix," according to the company.

Comparable to rhBMP-2

The product is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. The company adds that the product "functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques."

The planned study is a prospective, randomized, controlled, open-label, multi-center, parallel group study with the primary endpoint of radiographic interbody fusion, using CT-scans at 12 months, determined by an independent radiology expert panel.

“Huge Commercial Opportunity”

Company CEO Joost de Bruijn, Ph.D. said if the study is successful, a "huge commercial opportunity” will be opened.

Kuros Biosciences is a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ). The company partnered with the University of Zürich and the California Institute of Technology to develop the proprietary TG-Hook Technology. In early 2017 Kuros acquired Xpand Biotechnology, adding the MagnetOs family of bone grafts to the company's portfolio.


1 thought on “First Ever Drug/Bio Combo IND Approved by FDA for Lumbar Fusion

  1. Will this product have a black box warning like teriparitide since that has a similar MO as PTH? I’m sure the FDA will require those animal studies.

Leave a Reply to Mike Cancel reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.